I 115th CONGRESS 2d Session H. R. 5582 IN THE HOUSE OF REPRESENTATIVES April 23, 2018 Mr. Carter of Georgia (for himself, Mr. Loebsack , and Mr. Reed ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To direct the Secretary of Health and Human Services to conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for individuals enrolled in a plan under part C or D of the Medicare program.

1. Short title This Act may be cited at the Abuse Deterrent Access Act of 2018 . 2. Study on abuse-deterrent opioid formulations access barriers under Medicare (a) In general Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall conduct a study and submit to Congress a report on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in an MA–PD plan under part C of title XVIII of the Social Security Act or a prescription drug plan under part D of such title of such Act, taking into account any barriers preventing such individuals from accessing such formulations under such MA–PD or part D plans, such as cost-sharing tiers, fail-first requirements, and prior authorization requirements. (b) Definition of abuse-deterrent opioid formulation In this section, the term abuse-deterrent opioid formulation means an opioid with certain abuse-deterrent properties, such as physical or chemical barriers, agonist or antagonist combinations, aversion properties, delivery system mechanisms, or other features designed to prevent abuse of such opioid.